Tess Lin

1.2k total citations · 2 hit papers
14 papers, 785 citations indexed

About

Tess Lin is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Surgery. According to data from OpenAlex, Tess Lin has authored 14 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Cancer Research and 6 papers in Surgery. Recurrent topics in Tess Lin's work include Prostate Cancer Treatment and Research (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Adrenal and Paraganglionic Tumors (5 papers). Tess Lin is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Adrenal and Paraganglionic Tumors (5 papers). Tess Lin collaborates with scholars based in United States and Canada. Tess Lin's co-authors include Vivien Wong, Jessica Jensen, Nancy Stambler, Peter R. Carroll, Barry A. Siegel, Steven P. Rowe, Michael A. Gorin, Michael J. Morris, Frédéric Pouliot and Lawrence Saperstein and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Tess Lin

14 papers receiving 773 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY)

2021 244 citations Kenneth J. Pienta, Michael A. Gorin et al. The Journal of Urology profile →
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

2021 237 citations Michael J. Morris, Steven P. Rowe et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tess Lin United States	7	506	343	187	167	122	14	785
Jessica Jensen United States	5	471 0.9×	336 1.0×	186 1.0×	163 1.0×	119 1.0×	10	735
Ferdinando Calabria Italy	18	437 0.9×	481 1.4×	89 0.5×	138 0.8×	126 1.0×	49	868
Hans Christian Rischke Germany	17	711 1.4×	385 1.1×	130 0.7×	161 1.0×	84 0.7×	26	981
Thomas Armor United States	8	409 0.8×	460 1.3×	106 0.6×	128 0.8×	189 1.5×	16	685
Philipp E. Hartrampf Germany	16	379 0.7×	381 1.1×	98 0.5×	70 0.4×	245 2.0×	73	702
Lucia Zanoni Italy	15	638 1.3×	519 1.5×	174 0.9×	68 0.4×	173 1.4×	50	1.0k
Byung Hyun Byun South Korea	19	413 0.8×	575 1.7×	92 0.5×	83 0.5×	169 1.4×	46	902
Aurora Poon Australia	16	269 0.5×	328 1.0×	159 0.9×	78 0.5×	163 1.3×	32	800
Ameya Puranik India	13	165 0.3×	195 0.6×	75 0.4×	114 0.7×	144 1.2×	105	551
Bernhard Nilica Austria	17	420 0.8×	410 1.2×	84 0.4×	102 0.6×	327 2.7×	27	855

Countries citing papers authored by Tess Lin

Since Specialization

Citations

This map shows the geographic impact of Tess Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tess Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tess Lin more than expected).

Fields of papers citing papers by Tess Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tess Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tess Lin. The network helps show where Tess Lin may publish in the future.

Co-authorship network of co-authors of Tess Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Tess Lin. A scholar is included among the top collaborators of Tess Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tess Lin. Tess Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Morris, Michael J., Steven P. Rowe, Michael A. Gorin, et al.. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical Cancer Research. 27(13). 3674–3682. 237 indexed citations breakdown →

Pienta, Kenneth J., Michael A. Gorin, Steven P. Rowe, et al.. (2021). A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). The Journal of Urology. 206(1). 52–61. 244 indexed citations breakdown →

Pryma, Daniel A., Bennett B. Chin, Richard B. Noto, et al.. (2019). An update on overall survival from a multi-center, open-label, pivotal phase 2b study of AZEDRA® (iobenguane I 131) in patients with iobenguane scan positive locally advanced or metastatic pheochromocytoma/paraganglioma (PPGL). 60. 564–564. 1 indexed citations

Jiménez, Camilo, Ravinder K. Grewal, Gregory Ravizzini, et al.. (2019). SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA®) in Patients with Iobenguane Scan Positive Cancers. Journal of the Endocrine Society. 3(Supplement_1). 1 indexed citations

Morris, Michael J., Jeremy C. Durack, Ajjai Alva, et al.. (2019). Diagnostic performance of ¹⁸F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of ¹⁸F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. Journal of Clinical Oncology. 37(15_suppl). 5012–5012. 2 indexed citations

Morris, Michael J., Frédéric Pouliot, Lawrence Saperstein, et al.. (2019). A phase III, multicenter study to assess the diagnostic performance and clinical impact of ¹⁸F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR).. Journal of Clinical Oncology. 37(15_suppl). TPS5093–TPS5093. 6 indexed citations

Rowe, Steven P., Michael A. Gorin, Kenneth J. Pienta, et al.. (2019). Results from the OSPREY trial: A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer - Examination of Diagnostic AccuracY. 60. 586–586. 14 indexed citations

Pryma, Daniel A., Bennett B. Chin, Richard B. Noto, et al.. (2018). Efficacy and Safety of High-Specific-Activity ¹³¹I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. Journal of Nuclear Medicine. 60(5). 623–630. 191 indexed citations

Pryma, Daniel A., Bennett B. Chin, Richard B. Noto, et al.. (2018). Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.. Journal of Clinical Oncology. 36(15_suppl). 4005–4005. 3 indexed citations

10.

Morris, Michael J., Peter R. Carroll, Stephan Probst, et al.. (2018). A prospective phase 2/3 multicenter study of ¹⁸F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. Journal of Clinical Oncology. 36(15_suppl). TPS5092–TPS5092. 3 indexed citations

11.

Noto, Richard B., Daniel A. Pryma, Jessica Jensen, et al.. (2017). Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma. The Journal of Clinical Endocrinology & Metabolism. 103(1). 213–220. 42 indexed citations

12.

Adams, Kirkwood F., et al.. (2015). PILOT STUDY OF THE RELATIONSHIP OF AMBIENT COPEPTIN TO THE AQUARETIC EFFECTS OF TOLVAPTAN IN PATIENTS WITH HEART FAILURE. Journal of the American College of Cardiology. 65(10). A917–A917. 1 indexed citations

13.

Lin, Tess, Kirkwood F. Adams, & J. Herbert Patterson. (2014). Potential Roles of Vaptans in Heart Failure. Heart Failure Clinics. 10(4). 607–620. 6 indexed citations

14.

Lin, Tess, et al.. (2014). Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions. Journal of Clinical Medicine. 3(4). 1276–1290. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact